XLENTI
Dead / Abandoned — Abandoned — failure to respond (as of 03 Jan 2023)
What this means for you
This application is over — abandoned 15 Dec 2022. The name may be available, but check before relying on it — rights can also come from actual use, not only from the register.
Record
- Serial number
- 79326685
- Mark type
- Stylized text
- Filed
- 20 Sept 2021
- Abandoned
- 15 Dec 2022
Goods and services
- Class 001 — Chemicals: Chemical and biological substances for use in science and industry; nucleic acids; nucleic recombinant acids, synthetic deoxyribonucleic acids; chemical and biological reagents for non-medical purposes; chemical and biological reagents for scientific and research purposes; human and animal cells and parts thereof for non-medical purposes; microorganisms for non-medical purposes; human and animal cells and parts thereof for scientific and research purposes; microorganisms for scientific and research purposes; viral vectors for use in science and industry; lentiviruses, lentivirus particles and lentivirus plasmids, all for scientific and research purposes
- Class 005 — Pharmaceuticals: Chemical and biological reagents for medical and veterinary use; diagnostic and test reagents for medical and veterinary use; human and animal cells and parts thereof for medical and veterinary purposes; microorganisms for medical and veterinary purposes; viral vectors for medical and veterinary purposes; lentiviruses, lentivirus particles and lentivirus plasmids, all for medical and veterinary use
- Class 042 — Scientific and technological services: Design services relating to the creation and alteration of chemical and biological reagents; design services relating to the creation and alteration of nucleic recombinant acids and synthetic deoxyribonucleic acids; design services relating to the creation and alteration of recombinant viruses; design services relating to the creation and alteration of lentiviruses, lentivirus particles and lentivirus plasmids; research, development and bioengineering services relating to lentiviruses; drug discovery services; design services relating to the creation and alteration of cell lines, elementary cells and parts thereof; design services relating to the creation and alteration of viral vectors; information and advice relating to all the aforesaid services
Owner
Prosecution history
- 14 Feb 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 08 Nov 2024 — NEW REPRESENTATIVE AT IB RECEIVED
- 22 Jan 2024 — FINAL DECISION TRANSACTION PROCESSED BY IB
- 03 Jan 2024 — FINAL DISPOSITION NOTICE SENT TO IB
- 03 Jan 2024 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 16 May 2023 — NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
- 26 Apr 2023 — NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
- 26 Apr 2023 — NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
- 03 Jan 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 03 Jan 2023 — ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
- 03 Jan 2023 — ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
- 05 Jul 2022 — REFUSAL PROCESSED BY IB
- 14 Jun 2022 — NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
- 14 Jun 2022 — REFUSAL PROCESSED BY MPU
- 10 Jun 2022 — NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW